Latest Filings

Issuer Activity

Insider Overview :: Response Biomedical Corp (T:RBM) [?]
Business Focus: Biotechnology & Medical Research
Recent Price for RBM
CAD 3.50 0.00 (0.00%)
TSX Delayed 15 minutes
May 21 1041 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
3.50 5.75 0.0 5,269 22.96
1-Day Low 52-Week Low Yield Avg. Volume  
3.50 0.95 0.0% 3,979  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for RBM within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 20th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $3.60
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 300 $3.52
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 1,900 $3.57
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 100 $3.55
Mar 18/13 Mar 15/13 Adams, William James Direct Ownership Common Shares 10 - Acquisition in the public market 2,500 $3.50
Mar 18/13 Mar 15/13 Adams, William James Direct Ownership Common Shares 10 - Acquisition in the public market 1,000 $3.40
Mar 18/13 Mar 14/13 Severson, Clinton H. Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Thompson, Peter Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Keegan, Joseph D. Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Shuster, Lewis J. Direct Ownership Options 50 - Grant of options 20,000 $3.10
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for RBM within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 20th, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $3.60
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 300 $3.52
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 1,900 $3.57
Mar 20/13 Mar 19/13 Purvin, Jeffrey Leon Direct Ownership Common Shares 10 - Acquisition in the public market 100 $3.55
Mar 20/13 Jul 25/12 Purvin, Jeffrey Leon Direct Ownership Common Shares 00 - Opening Balance-Initial SEDI Report    
Mar 18/13 Mar 14/13 Severson, Clinton H. Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Thompson, Peter Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Keegan, Joseph D. Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Shuster, Lewis J. Direct Ownership Options 50 - Grant of options 20,000 $3.10
Mar 18/13 Mar 14/13 Wang, Jonathan Jian Direct Ownership Options 50 - Grant of options 20,000 $3.10
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for RBM on May 17, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Biotechnology & Medical Research
Key People
Peter A. Thompson
Executive Chairman of the Board 		Jeffrey L. Purvin
Chief Executive Officer, Director 		W. J. Adams
Chief Financial Officer, Corporate Secretary
Tim Shannon
Senior Vice President - World Wide Sales and Marketing 		Patricia Massitti
Vice President - Administration Corporate Communication 		Barbara K. Steen
Vice President - Research and Development
Anastasios Tsonis
Corporate Controller 		   
Company Contact
Address: 1781-75th AVENUE W
VANCOUVER BC V6P 6P2
Tel: 1-604-4566010
Website: www.responsebio.com
IR: www.responsebio.com/investors_stock_information.asp?menu=1&submenu=1
Business Overview
Response Biomedical Corporation (Response) develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. RAMP represents a paradigm in diagnostics that provides sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The RAMP system is a platform technology that combines a sensitive, portable fluorescence detection system with simple lateral flow immunoassays. RAMP maintains key positive attributes of lateral flow immunoassays - simplicity, specificity, reliability and rapid results - but includes a method to overcome the performance limitations of early generation immunoassays that suffer from relatively poor sensitivity and precision.
Competitors with Recent Insider Filings
QLT (T:QLT)
EnWave (V:ENW)
iCo Therapeutics (V:ICO)
 
Response Biomedical Corp Insider Report Only $20.00